BiotechTube
Home/reMYND/Gerard Griffioen, PhD
GG

Gerard Griffioen, PhD

CSO

reMYND

Therapeutic Areas

Alzheimer's DiseaseHuntington's DiseaseAmyotrophic Lateral Sclerosis (ALS)

reMYND Pipeline

DrugIndicationPhase
REM392 (Alzheimer's Program)Alzheimer's DiseasePre-clinical
Huntington's ProgramHuntington's DiseasePre-clinical
Discovery ProgramAmyotrophic Lateral Sclerosis (ALS)Discovery

Leadership Team at reMYND

FS
Floor Stam, PhD
CEO
CF
Chris Freitag, MD
Clinical Advisor
NV
Nancy Van Osselaer, PhD
Development Advisor
KP
Katrien Princen, PhD
Head of Operations
SL
Sara Lambrechts
Head of Finance
View full reMYND profile